A randomized, double-blind, placebo-controlled, 2-period crossover study to evaluate the effect of intranasal esketamine on cognitive functioning in healthy subjects

Trial Profile

A randomized, double-blind, placebo-controlled, 2-period crossover study to evaluate the effect of intranasal esketamine on cognitive functioning in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Oct 2014

At a glance

  • Drugs Esketamine (Primary)
  • Indications Major depressive disorder
  • Focus Pharmacodynamics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 24 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 28 Aug 2014 Planned End Date changed from 1 Jul 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.
    • 07 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top